Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer
Authors:
- 7 August 2007
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 47 (2) , 88-99
Abstract
Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as p53, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor samples. Approximately 11% of patients exhibited mutations in p53. Women with mutations had a significantly younger age of diagnosis (P = 0.01) and a greater incidence of tumors classified as stage II or higher (P = 0.002). More women with mutations had a history of smoking (55%) compared to women without mutations (39%). Although none of the genotypes alone were associated with p53 mutations, positive smoking history was associated with p53 mutations in women with the GSTM1 null allele [OR = 3.54; 95% CI = 0.97–12.90 P = 0.06] compared to women with the wild‐type genotype and smoking history [OR = 0.62, 95% CI = 0.19–2.07], although this association did not reach statistical significance. To test for gene–gene interactions, our exploratory analysis in the Caucasian cases suggested that individuals with the combined GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were more likely to harbor mutations in p53 [OR = 4.94; 95% CI = 1.11–22.06]. Our results suggest that gene–smoking and gene–gene interactions may impact the prevalence of p53 mutations in breast tumors. Elucidating the etiology of breast cancer as a consequence of common genetic polymorphisms and the genotoxic effects of smoking will enable us to improve the design of prevention strategies, such as lifestyle modifications, in genetically susceptible subpopulations.Keywords
This publication has 65 references indexed in Scilit:
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Clinical Cancer Research, 2006
- TP53mutations in breast cancer tumors of patients from Rio de Janeiro, Brazil: Association with risk factors and tumor characteristicsInternational Journal of Cancer, 2002
- The IARC TP53 database: New online mutation analysis and recommendations to usersHuman Mutation, 2002
- TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesisSeminars in Cancer Biology, 2001
- Genetic polymorphism at the glutathione S‐tranferase (GST) P1 locus is a breast cancer risk modifierInternational Journal of Cancer, 2001
- Proportion of Breast Cancer Cases in the United States Explained by Well-Established Risk FactorsJNCI: Journal of the National Cancer Institute, 1995
- Multivariate Adaptive Regression SplinesThe Annals of Statistics, 1991
- Metabolism and activation of carcinogenic polycyclic hydrocarbons by human mammary cellsBiochemical and Biophysical Research Communications, 1980
- Estimating the Dimension of a ModelThe Annals of Statistics, 1978